These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 17053207

  • 1. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
    Kardos P, Wencker M, Glaab T, Vogelmeier C.
    Am J Respir Crit Care Med; 2007 Jan 15; 175(2):144-9. PubMed ID: 17053207
    [Abstract] [Full Text] [Related]

  • 2. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug 15; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 3. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.
    Respir Med; 2013 Apr 15; 107(4):542-9. PubMed ID: 23337300
    [Abstract] [Full Text] [Related]

  • 4. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators.
    N Engl J Med; 2007 Feb 22; 356(8):775-89. PubMed ID: 17314337
    [Abstract] [Full Text] [Related]

  • 5. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP, Yang L, Wu YM, Chen P, Wen ZG, Huang WJ, Shi Y, Wang CZ, Huang SG, Sun TY, Wang GF, Xiong SD, Zhong NS.
    Chest; 2007 Dec 22; 132(6):1756-63. PubMed ID: 17951625
    [Abstract] [Full Text] [Related]

  • 6. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
    Fang LZ, Liang X, Zhang JQ, Liu L, Fu WP, Zhao ZH, Dai LM.
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov 22; 31(11):811-4. PubMed ID: 19080533
    [Abstract] [Full Text] [Related]

  • 7. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
    Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM, POET-COPD Investigators.
    N Engl J Med; 2011 Mar 24; 364(12):1093-1103. PubMed ID: 21428765
    [Abstract] [Full Text] [Related]

  • 8. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, Prillaman B, Shah T.
    Ann Allergy Asthma Immunol; 1999 Mar 24; 82(3):257-65. PubMed ID: 10094216
    [Abstract] [Full Text] [Related]

  • 9. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
    Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE.
    Respir Med; 2012 Jan 24; 106(1):91-101. PubMed ID: 22040533
    [Abstract] [Full Text] [Related]

  • 10. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr 24; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 11. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR, Albers JM, Verblackt HW, Costongs RJ, Westers P.
    Fam Pract; 2007 Apr 24; 24(2):181-8. PubMed ID: 17251178
    [Abstract] [Full Text] [Related]

  • 12. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD, Korean Academy of Tuberculosis and Respiratory Diseases study group, Korea Chronic Obstructive Pulmonary Disease study group.
    Respir Med; 2012 Mar 24; 106(3):382-9. PubMed ID: 21975275
    [Abstract] [Full Text] [Related]

  • 13. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
    Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, INSPIRE Investigators.
    Am J Respir Crit Care Med; 2008 Jan 01; 177(1):19-26. PubMed ID: 17916806
    [Abstract] [Full Text] [Related]

  • 14. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM.
    Am J Respir Crit Care Med; 2008 Aug 15; 178(4):332-8. PubMed ID: 18511702
    [Abstract] [Full Text] [Related]

  • 15. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
    Murray J, Rosenthal R, Somerville L, Blake K, House K, Baitinger L, VanderMeer A, Dorinsky P.
    Ann Allergy Asthma Immunol; 2004 Oct 15; 93(4):351-9. PubMed ID: 15521371
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
    Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, Banerji D.
    Lancet Respir Med; 2013 Mar 15; 1(1):51-60. PubMed ID: 24321804
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, Mechali D, Chan R, Pedersen S.
    Clin Ther; 2008 Aug 15; 30(8):1492-504. PubMed ID: 18803991
    [Abstract] [Full Text] [Related]

  • 18. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
    Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C, TRial of Inhaled STeroids ANd long-acting beta2 agonists study group.
    Lancet; 2003 Feb 08; 361(9356):449-56. PubMed ID: 12583942
    [Abstract] [Full Text] [Related]

  • 19. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K, Janson C, Lisspers K, Jørgensen L, Stratelis G, Telg G, Ställberg B, Johansson G.
    J Intern Med; 2013 Jun 08; 273(6):584-94. PubMed ID: 23495860
    [Abstract] [Full Text] [Related]

  • 20. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ.
    Thorax; 2008 Jul 08; 63(7):592-8. PubMed ID: 18245142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.